Hostname: page-component-89b8bd64d-ktprf Total loading time: 0 Render date: 2026-05-13T06:43:13.890Z Has data issue: false hasContentIssue false

Reversion of CYP450 monooxygenase-mediated acetamiprid larval resistance in dengue fever mosquito, Aedes aegypti L.

Published online by Cambridge University Press:  24 February 2022

Roopa Rani Samal
Affiliation:
Department of Zoology, Acharya Narendra Dev College, University of Delhi, Kalkaji, New Delhi 110019, India
Kungreilu Panmei
Affiliation:
Department of Zoology, Acharya Narendra Dev College, University of Delhi, Kalkaji, New Delhi 110019, India
P. Lanbiliu
Affiliation:
Department of Zoology, Acharya Narendra Dev College, University of Delhi, Kalkaji, New Delhi 110019, India
Sarita Kumar*
Affiliation:
Department of Zoology, Acharya Narendra Dev College, University of Delhi, Kalkaji, New Delhi 110019, India
*
Author for correspondence: Sarita Kumar, Email: sarita.sanjay90@gmail.com; saritakumar@andc.du.ac.in
Rights & Permissions [Opens in a new window]

Abstract

Aedes-borne diseases are on the rampant rise despite continued application of chemical insecticide-based interventions. The appearance of high degree of insecticide resistance in Aedes species and noxious effects on environment and non-targets have raised further concerns. Among new chemical interventions, neonicotinoids are considered a safe and effective approach. The present study investigated the control potency of acetamiprid and development of resistance in Aedes aegypti larvae; and the involvement of CYP450 monooxygenases in inducing resistance. The early fourth instars of Ae. aegypti parent susceptible strain (PS) were selected with acetamiprid for 15 generations (ACSF strain) increasing the resistance to 19.74-fold in ACSF-10 and 36.71-fold in ACSF-15. The ACSF-10 larvae were assayed with acetamiprid combined with piperonyl butoxide (PBO) in three different ratios (1:1, 1:5 and 1:10) and selected for next five generations with 1:10 combination. Selection with synergized acetamiprid (APSF strains) reversed as well as reduced the rate of resistance development resulting in only 1.35-fold resistance in APSF-15. The APSF strains showed %monooxygenase dependency ranging from 86.71 to 96.72%. The estimation of the monooxygenases levels in parent and selected larvae showed increased monooxygenase level in the ACSF strains by 2.42–2.87-fold. The APSF-15 strains exhibited 57.95% lower enzyme production than ACSF-15 strain. The reduction and reversion of resistance by using PBO and the elevated levels of monooxygenases in ACSF and reduction in APSF strains recommend the involvement of CYP450-mediated mechanism in the development of acetamiprid resistance in Ae. aegypti. These studies could help in devising resistance management strategies in order to preserve the efficiency of pre-existing insecticides.

Information

Type
Research Paper
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press
Figure 0

Figure 1. Dosage-mortality regression lines on selection of Aedes aegypti early fourth instars with acetamiprid for successive generations. PS, parent susceptible strain; ACSF-5, Acetamiprid Larval-Selected Filial-5; ACSF-10, Acetamiprid Larval-Selected Filial-10; ACSF-15, Acetamiprid Larval-Selected Filial-15.

Figure 1

Table 1. LC50 and LC90 (in mg litre−1) values of acetamiprid against early fourth instars of Aedes aegypti when selected with acetamiprid for 15 successive generations

Figure 2

Table 2. Larval LC50 and LC90 (in mg ml−1) of ACSF-10 strain of Aedes aegypti when assayed with acetamiprid combined with PBO in different ratios

Figure 3

Figure 2. Resistance ratios in successive generations of Aedes aegypti larvae. ACSF, parent susceptible strain selected with acetamiprid alone (ACSF) for 15 generations; APSF, ACSF-10 strain selected with acetamiprid + PBO(1:10) for next five generations.

Figure 4

Table 3. Larval LC50 and LC90 (in mg litre−1) of ACSF-10 strain of Aedes aegypti when selected with acetamiprid alone and acetamiprid + PBO (1:10) for five successive generations

Figure 5

Table 4. Per cent dependency on monooxygenase in Aedes aegypti early fourth instar when selected with acetamiprid + PBO (1:10)

Figure 6

Figure 3. Box plot distribution of range of P450 monooxygenase (OD min−1 μg−1 of protein) in the larvae of PS, ACSF-5, ACSF-10, ACSF-15 and APSF-15 strains of Aedes aegypti. Middle line between the boxes represents the median; upper and lower boxes represent the 25 and 75 percentiles of the data; whiskers represent the standard error of the mean; the dots above and below the whiskers represent the outliers. PS, parent strain; ACSF-5, Acetamiprid Larval-Selected Filial-5; ACSF-10, Acetamiprid Larval-Selected Filial-10; ACSF-15, Acetamiprid Larval-Selected Filial-15; APSF-15, Acetamiprid + PBO Larval-Selected Filial-10.

Figure 7

Table 5. Level of monooxygenases in parent susceptible and selected strains of Aedes aegypti

Figure 8

Figure 4. Frequency distribution of absorbance values of P450 monooxygenase mmol min−1 mg−1 of protein in the PS, ACSF-5, ACSF-10, ACSF-15 and APSF-15 strains of Aedes aegypti. Susceptibility threshold based on maximum absorbance in PS strain. Shaded region represents the resistant population (beyond the threshold). N, number of larvae; RP, resistant population; PS, parent strain; ACSF-5, Acetamiprid Larval-Selected Filial-5; ACSF-10, Acetamiprid Larval-Selected Filial-10; ACSF-15, Acetamiprid Larval-Selected Filial-15; APSF-15, Acetamiprid + PBO Larval-Selected Filial-10.